Hydroxyzine has not been directly proven to cause dementia, but it belongs to a class of medications with anticholinergic properties that are linked to increased dementia risk, particularly in older adults. The concern is real enough that many clinical guidelines now recommend against using hydroxyzine in people over 65.
Why Hydroxyzine Raises Concern
Hydroxyzine is a first-generation antihistamine commonly prescribed for anxiety, itching, and sleep. Unlike newer antihistamines like cetirizine (Zyrtec) or loratadine (Claritin), it easily crosses into the brain, where it blocks a chemical messenger called acetylcholine. Acetylcholine plays a central role in memory formation and learning. When a drug blocks it, the result can be brain fog, confusion, and difficulty with short-term memory.
This anticholinergic activity is what puts hydroxyzine in the same risk category as certain bladder medications, older antidepressants, and sleep aids like diphenhydramine (Benadryl). In fact, hydroxyzine and similar sedating antihistamines account for nearly 59% of anticholinergic drug use in nursing home settings, making them one of the most common sources of this type of chemical exposure in older adults.
What Large Studies Show
A nationwide cohort study published in Frontiers in Aging Neuroscience looked at the relationship between first-generation antihistamine use and dementia. Overall, the link was not statistically significant for the general population: the adjusted hazard ratio was 1.025, meaning essentially no meaningful increase in risk across all age groups combined. Even use beyond four years did not produce a significant increase in the full population.
But the picture changes sharply for people 65 and older. In that age group, antihistamine users had a 78% higher risk of developing dementia compared to non-users. The elevated risk applied to all major types of dementia: Alzheimer’s disease (81% higher risk), vascular dementia (66% higher), and other forms (51% higher). Being male or having multiple existing health conditions further increased the risk.
Dose Matters More Than You Might Think
A 2024 study in the Journal of Allergy and Clinical Immunology: In Practice examined how cumulative dose affects dementia risk in allergy patients. The findings showed a clear dose-response pattern for first-generation antihistamines like hydroxyzine. At low cumulative doses, the risk increase was modest, around 13%. At moderate cumulative doses, the risk climbed to 29% higher than non-users. At the highest cumulative doses, the risk jumped to 51% higher.
Second-generation antihistamines showed a similar trend but with consistently lower numbers: a 11% increase at low doses, 19% at moderate doses, and 26% at high doses. So while newer antihistamines are not completely free of concern at high cumulative exposure, first-generation options like hydroxyzine carry roughly double the additional risk at the highest dose levels.
Short-Term Cognitive Effects vs. Dementia
It is worth separating two different problems. Hydroxyzine can cause immediate, reversible cognitive side effects: drowsiness, mental slowing, confusion, and memory difficulty. These effects happen because the drug is actively blocking acetylcholine in the brain, and they typically improve once the medication is stopped or the dose is reduced. In older adults, these symptoms can look a lot like early dementia and sometimes get misidentified as such.
The deeper concern is whether years of repeated anticholinergic exposure cause lasting structural changes in the brain that don’t reverse. The cohort data suggests this is plausible, especially in people over 65, but the research cannot fully rule out other explanations. People who take hydroxyzine long-term may also have underlying anxiety, insomnia, or other conditions that independently affect brain health. What the data does make clear is that higher cumulative exposure correlates with higher risk, and that this pattern holds even after adjusting for other health factors.
Age Is the Biggest Factor
The research consistently points to age as the dividing line. For adults under 65, the available evidence does not show a meaningful increase in dementia risk from antihistamine use, even over several years. For adults 65 and older, the risk becomes significant and applies across dementia subtypes. This likely reflects the aging brain’s reduced ability to compensate for anticholinergic interference, combined with lower baseline acetylcholine levels that naturally decline with age.
This is why organizations like the American Geriatrics Society include hydroxyzine on the Beers Criteria, a list of medications considered potentially inappropriate for older adults. The recommendation is not based on hydroxyzine being uniquely dangerous, but on the broader principle that anticholinergic drugs pose outsized cognitive risks in aging brains.
Safer Alternatives for Anxiety and Sleep
If you are taking hydroxyzine for anxiety or insomnia and are concerned about cognitive effects, there are alternatives worth discussing with your prescriber, particularly if you are over 65.
- For insomnia: Cognitive behavioral therapy for insomnia (CBT-I) is considered the gold standard treatment, with effects that match or exceed sleep medications and persist after treatment ends. For older adults who need a medication, melatonin or synthetic melatonin-based options are generally preferred for difficulty falling asleep. Low-dose doxepin (at very low doses, under 6 mg) is another option for people who wake frequently during the night.
- For allergies: Second-generation antihistamines like cetirizine, loratadine, or fexofenadine carry lower anticholinergic burden. They are not zero-risk at high cumulative doses, but the data shows roughly half the additional dementia risk compared to first-generation options.
- For anxiety: Non-anticholinergic options exist across several medication classes. The best fit depends on whether the anxiety is situational, chronic, or related to another condition.
What This Means Practically
Occasional hydroxyzine use for an allergic reaction or a particularly anxious night is unlikely to have lasting cognitive consequences at any age. The concern centers on regular, long-term use, especially in people over 65. If you have been taking hydroxyzine daily for months or years, the cumulative anticholinergic exposure is what drives the increased risk seen in studies. Stopping abruptly is not necessarily the right move either, since the conditions it treats also affect quality of life. The practical step is a conversation about whether a lower-risk alternative could work for your situation, and whether the benefits of continued use outweigh the potential cognitive cost over time.